Rare tumors present several challenges, including lack of evidence based treatment recommendations, unwillingness of insurance companies to support unproven therapies, and keen competition for translational research support that may benefit only a small proportion of all cancer patients. Neuroendocrine tumors (NETs) targeted in this proposal are rare tumors that face all of these challenges. NETs arise from the diffuse neuroendocrine system, occur in both adults and children, and are increasing in both incidence and prevalence in the United States. The University of Iowa is one of only a handful of academic or private institutions in the US where patients with NETs are diagnosed, treated, and regularly followed in a comprehensive manner. A multi-disciplinary NET clinic, an IRB approved registry and database, and a growing translational research program are housed at the University of Iowa. We have collaborated with pharmaceutical and biotech companies, patient support groups, and other research institutions whose expertise complements our clinical and translational expertise, to build a neuroendocrine tumor Center of Excellence. Iowa is poised to house the first SPORE in neuroendocrine tumors where academic, industry, and philanthropic organizations will partner with NCI to increase the length and quality of life for these unique patients. Our Overall Specific Aims are: 1. Support innovative translational research in Neuroendocrine Tumors. 2. Provide support to translational investigators through interactive cores. 3. Enlist and encourage new translational researchers in neuroendocrine tumors through developmental projects and career development. 4. Promote early and accurate diagnosis through outreach to physicians and advocacy groups.

Public Health Relevance

Neuroendocrine tumors are slow growing, well-differentiated, yet relentlessly progressing malignancies that demonstrate near complete resistance to chemotherapeutic agents. A Neuroendocrine Tumor SPORE at the University of Iowa will result in advances that have an extraordinarily large clinical impact on the length and quality of life fo a rapidly growing population of patients with neuroendocrine tumors.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (J1))
Program Officer
Nothwehr, Steven F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Iowa
Schools of Medicine
Iowa City
United States
Zip Code
Mansour, John C; Chavin, Kenneth; Morris-Stiff, Gareth et al. (2018) Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. HPB (Oxford) :
Keck, Kendall J; Maxwell, Jessica E; Utria, Alan F et al. (2018) The Distal Predilection of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 25:3207-3213
Menda, Yusuf; Madsen, Mark T; O'Dorisio, Thomas M et al. (2018) 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. J Nucl Med 59:1692-1698
Pelletier, Daniel J; Czeczok, Thomas W; Bellizzi, Andrew M (2018) A monoclonal antibody against SV40 large T antigen (PAb416) does not label Merkel cell carcinoma. Histopathology 73:162-166
Keck, Kendall J; Breheny, Patrick; Braun, Terry A et al. (2018) Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases. Surgery 163:232-239
Lee, Dongyoul; Li, Mengshi; Bednarz, Bryan et al. (2018) Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy. Radiat Res 190:236-247
Madsen, Mark T; Menda, Yusuf; O'Dorisio, Thomas M et al. (2018) Technical Note: Single time point dose estimate for exponential clearance. Med Phys 45:2318-2324
Czeczok, Thomas W; Stashek, Kristen M; Maxwell, Jessica E et al. (2018) Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin. Appl Immunohistochem Mol Morphol 26:94-100
Scott, Aaron T; Howe, James R (2018) Management of Small Bowel Neuroendocrine Tumors. J Oncol Pract 14:471-482
Strosberg, Jonathan; Wolin, Edward; Chasen, Beth et al. (2018) Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol 36:2578-2584

Showing the most recent 10 out of 24 publications